A case study of personalized therapy for osteosarcoma.

Area of Science:

• Oncology
• Comparative Medicine
• Pharmacology

Background:

• Sarcomas exhibit significant biological heterogeneity, complicating targeted therapy development.
• Personalized treatment approaches are crucial for effective sarcoma management.
• A case study in a canine with osteosarcoma is presented to illustrate a personalized therapy process.

Purpose of the Study:

• To outline a process for personalizing sarcoma therapy.
• To identify the most effective targeted therapy for an individual canine osteosarcoma patient.
• To evaluate the efficacy and tolerability of dasatinib in a canine model.

Main Methods:

• Rapid establishment of a primary tumor cell culture from a canine osteosarcoma.
• Functional characterization of the tumor to identify effective targeted therapies.
• Administration of adjuvant dasatinib (Src inhibitor) following chemotherapy.
• Pharmacokinetic studies to determine therapeutic serum concentrations and optimal dosage.

Main Results:

• Dasatinib was identified as the most effective targeted therapy for the individual canine.
• The canine received adjuvant dasatinib for 26 weeks at a tolerable dose of 0.75 mg/kg/day.
• Pharmacokinetic studies confirmed achievement of therapeutic serum concentrations.
• The canine patient showed no evidence of recurrent disease 24 months after initial diagnosis.

Conclusions:

• The described personalized therapy approach is effective in a canine osteosarcoma case.
• The methodology is potentially applicable to other solid tumors in canines.
• This approach may also be translatable to human solid tumor treatment.